# Bibliometric Analysis of the Epidemiological Research on Alzheimer’s Disease Treatment

## TL;DR

This paper uses bibliometric analysis to study trends in Alzheimer’s disease research, focusing on publication growth and shifts in treatment approaches.

## Contribution

The study provides a comprehensive bibliometric overview of Alzheimer’s research, highlighting institutional contributions and evolving therapeutic focus.

## Key findings

- There is a notable increase in Alzheimer’s research publications in 2022 following the COVID-19 pandemic.
- Leading institutions include Karolinska Institutet, Columbia University, UCSF, and the University of Pittsburgh.
- Research is shifting from symptomatic treatments to disease-modifying therapies.

## Abstract

Alzheimer's disease presents a complex global health issue. It is characterized by a decline in cognitive function, starting with memory impairment, and extending to impact reasoning, language abilities, and spatial awareness. Despite decades of research, Alzheimer's disease remains a global challenge lacking long-term treatments. Institutions like the Karolinska Institutet, Columbia University, the University of California San Francisco (UCSF), and the University of Pittsburgh contribute significantly to Alzheimer's research, with a growth in publications in 2022 post-COVID-19. While current treatments offer symptomatic relief, there's a need for disease-modifying therapies targeting its mechanisms. This analysis aims to provide a comprehensive overview of the available research and medical literature on Alzheimer’s disease by employing bibliometric methods to identify publication trends, leading research institutions, and the evolving focus from symptomatic treatments to disease-modifying therapies. This paper seeks to analyze the research papers on Alzheimer’s disease and catalog the metadata associated with each paper.